157 related articles for article (PubMed ID: 25916054)
1. Feasibility Assessment of Modified FOLFOX-6 as adjuvant treatment after resection of liver metastases from colorectal cancer: analyses of a multicenter phase II clinical trial (Miyagi-HBPCOG Trial-001).
Katayose Y; Yamamoto K; Nakagawal K; Takemura S; Takahashi M; Nakamura R; Shimamura H; Rikiyama T; Egawa S; Yoshda H; Motoi F; Naitoh T; Unno M
Hepatogastroenterology; 2015; 62(138):303-8. PubMed ID: 25916054
[TBL] [Abstract][Full Text] [Related]
2. Postoperative hepatic arterial chemotherapy in high-risk patients as adjuvant treatment after resection of colorectal liver metastases - a randomized phase II/III trial - PACHA-01 (NCT02494973).
Goéré D; Pignon JP; Gelli M; Elias D; Benhaim L; Deschamps F; Caramella C; Boige V; Ducreux M; de Baere T; Malka D
BMC Cancer; 2018 Aug; 18(1):787. PubMed ID: 30081865
[TBL] [Abstract][Full Text] [Related]
3. A randomized phase II/III trial comparing hepatectomy followed by mFOLFOX6 with hepatectomy alone as treatment for liver metastasis from colorectal cancer: Japan Clinical Oncology Group Study JCOG0603.
Kanemitsu Y; Kato T; Shimizu Y; Inaba Y; Shimada Y; Nakamura K; Sato A; Moriya Y;
Jpn J Clin Oncol; 2009 Jun; 39(6):406-9. PubMed ID: 19389795
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal cancer: the RESPECT trial.
Tabernero J; Garcia-Carbonero R; Cassidy J; Sobrero A; Van Cutsem E; Köhne CH; Tejpar S; Gladkov O; Davidenko I; Salazar R; Vladimirova L; Cheporov S; Burdaeva O; Rivera F; Samuel L; Bulavina I; Potter V; Chang YL; Lokker NA; O'Dwyer PJ
Clin Cancer Res; 2013 May; 19(9):2541-50. PubMed ID: 23532888
[TBL] [Abstract][Full Text] [Related]
5. A multicenter phase II trial of mFOLFOX6 plus bevacizumab to treat liver-only metastases of colorectal cancer that are unsuitable for upfront resection (TRICC0808).
Uetake H; Yasuno M; Ishiguro M; Kameoka S; Shimada Y; Takahashi K; Watanabe T; Muro K; Baba H; Yamamoto J; Mizunuma N; Tamagawa H; Mochizuki I; Kinugasa Y; Kikuchi T; Sugihara K
Ann Surg Oncol; 2015 Mar; 22(3):908-15. PubMed ID: 25465375
[TBL] [Abstract][Full Text] [Related]
6. A combination of oral uracil-tegafur plus leucovorin (UFT + LV) is a safe regimen for adjuvant chemotherapy after hepatectomy in patients with colorectal cancer: safety report of the UFT/LV study.
Saiura A; Yamamoto J; Hasegawa K; Oba M; Takayama T; Miyagawa S; Ijichi M; Teruya M; Yoshimi F; Kawasaki S; Koyama H; Makuuchi M; Kokudo N
Drug Discov Ther; 2014 Feb; 8(1):48-56. PubMed ID: 24647158
[TBL] [Abstract][Full Text] [Related]
7. Feasibility and short-term outcome of adjuvant FOLFOX after resection of colorectal liver metastases.
Sakamoto Y; Beppu T; Miyamoto Y; Okabe H; Ida S; Imai K; Chikamoto A; Watanabe M; Takamori H; Baba H
J Hepatobiliary Pancreat Sci; 2013 Mar; 20(3):307-12. PubMed ID: 22610308
[TBL] [Abstract][Full Text] [Related]
8. mFOLFOX6 plus bevacizumab to treat liver-only metastases of colorectal cancer that are unsuitable for upfront resection (TRICC0808): a multicenter phase II trial comprising the final analysis for survival.
Yasuno M; Uetake H; Ishiguro M; Mizunuma N; Komori T; Miyata G; Shiomi A; Kagimura T; Sugihara K
Int J Clin Oncol; 2019 May; 24(5):516-525. PubMed ID: 30612267
[TBL] [Abstract][Full Text] [Related]
9. Feasibility of mFOLFOX6 as the adjuvant treatment after curative resection of metastases from colorectal cancer in Japanese patients.
Machida N; Yoshizaki K; Boku N; Yamazaki K; Onozawa Y; Fukutomi A; Yasui H; Taku K
Int J Clin Oncol; 2013 Apr; 18(2):279-84. PubMed ID: 22367535
[TBL] [Abstract][Full Text] [Related]
10. Prospective pilot study of neoadjuvant chemotherapy with 5-fluorouracil, folinic acid and oxaliplatin in resectable liver metastases of colorectal cancer. Analysis of 42 neoadjuvant chemotherapies.
Lorenz M; Staib-Sebler E; Gog C; Proschek D; Jauch KW; Ridwelski K; Hohenberger W; Gassel HJ; Lehmann U; Vestweber KH; Padberg W; Zamzow K; Müller HH
Zentralbl Chir; 2003 Feb; 128(2):87-94. PubMed ID: 12632273
[TBL] [Abstract][Full Text] [Related]
11. Liver resectability of advanced liver-limited colorectal liver metastases following mFOLFOX6 with bevacizumab (KSCC0802 Study).
Beppu T; Emi Y; Tokunaga S; Oki E; Shirabe K; Ueno S; Kuramoto M; Kabashima A; Takahashi I; Samura H; Eguchi S; Akagi Y; Natsugoe S; Ogata Y; Kakeji Y; Baba H; Maehara Y;
Anticancer Res; 2014 Nov; 34(11):6655-62. PubMed ID: 25368271
[TBL] [Abstract][Full Text] [Related]
12. A randomized phase II study of combination therapy with S-1, oral leucovorin, and oxaliplatin (SOL) and mFOLFOX6 in patients with previously untreated metastatic colorectal cancer.
Yamazaki K; Kuwano H; Ojima H; Otsuji T; Kato T; Shimada K; Hyodo I; Nishina T; Shirao K; Esaki T; Ohishi T; Denda T; Takeuchi M; Boku N
Cancer Chemother Pharmacol; 2015 Mar; 75(3):569-77. PubMed ID: 25575764
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant treatment with weekly high-dose 5-fluorouracil as a 24h-infusion, folinic acid and biweekly oxaliplatin in patients with primary resectable liver metastases of colorectal cancer: long-term results of a phase II trial.
Boxberger F; Albrecht H; Konturek PC; Reulbach U; Maennlein G; Meyer T; Hohenberger W; Hahn EG; Wein A
Med Sci Monit; 2010 Feb; 16(2):CR49-55. PubMed ID: 20110914
[TBL] [Abstract][Full Text] [Related]
14. Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study.
Taïeb J; Artru P; Paye F; Louvet C; Perez N; André T; Gayet B; Hebbar M; Goebel FM; Tournigand C; Parc R; de Gramont A
J Clin Oncol; 2005 Jan; 23(3):502-9. PubMed ID: 15659495
[TBL] [Abstract][Full Text] [Related]
15. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
[TBL] [Abstract][Full Text] [Related]
16. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).
Schmoll HJ; Cunningham D; Sobrero A; Karapetis CS; Rougier P; Koski SL; Kocakova I; Bondarenko I; Bodoky G; Mainwaring P; Salazar R; Barker P; Mookerjee B; Robertson J; Van Cutsem E
J Clin Oncol; 2012 Oct; 30(29):3588-95. PubMed ID: 22965961
[TBL] [Abstract][Full Text] [Related]
17. Prophylactic adjuvant hepatic arterial infusion chemotherapy reduced hepatic metastases from Stage III colorectal cancer after curative resection.
Feng WM; Tang CW; Huang SX; Zheng YY; Bao Y; Wang Y; Tao YL
Hepatogastroenterology; 2012 Jun; 59(116):1087-90. PubMed ID: 22328287
[TBL] [Abstract][Full Text] [Related]
18. Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure.
Boige V; Malka D; Elias D; Castaing M; De Baere T; Goere D; Dromain C; Pocard M; Ducreux M
Ann Surg Oncol; 2008 Jan; 15(1):219-26. PubMed ID: 17896145
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of adjuvant FOLFOX therapy for stage III colon cancer in Japan based on the MOSAIC trial.
Shiroiwa T; Takeuchi T; Fukuda T; Shimozuma K; Ohashi Y
Value Health; 2012; 15(2):255-60. PubMed ID: 22433756
[TBL] [Abstract][Full Text] [Related]
20. [The clinical outcome of mFOLFOX6 treatment for colorectal cancer patients who underwent resection of liver metastasis -comparison between synchronous and metachronous liver metastasis].
Honjou H; Ishibashi K; Okada N; Tajima Y; Ishiguro T; Kuwabara K; Ohsawa T; Kumamoto K; Tsuji Y; Haga N; Iwama T; Ishida H
Gan To Kagaku Ryoho; 2011 Nov; 38(12):2216-9. PubMed ID: 22202335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
